IIT2018-26 -Hendifar-NETCx: A Descriptive, Multicenter, Single-arm, Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain
Latest Information Update: 01 Jan 2021
At a glance
- Drugs Telotristat etiprate (Primary)
- Indications Malignant carcinoid syndrome; Neuroendocrine tumours
- Focus Pharmacodynamics
- 29 Dec 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 09 Aug 2020 Planned primary completion date changed from 1 Aug 2022 to 1 Nov 2022.
- 09 Aug 2020 Planned initiation date changed from 1 Jul 2020 to 1 Oct 2020.